Salmon calcitonin acetate (SCA) is clinically used to treat osteoporosis in postmenopausal women. SCA exhibits anti-osteoporotic, anti-resorptive, anti-diabetic, and chondroprotective activities. In obese animal models, SCA decreases body weight, decreases levels of plasma insulin and leptin, and improves fasting glycemia, preventing insulin resistance. In cartilage explants, SCA increases cAMP release and inhibits cartilage turnover and hypertrophy. In other animal models, SCA decreases collagen type II degradation, subchondral bone damage, and cartilage loss.